Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor

BACKGROUND: Structure-based drug design (SBDD) can accelerate inhibitor lead design and optimization, and efficient methods including protein purification, characterization, crystallization, and high-resolution diffraction are all needed for rapid, iterative structure determination. Janus kinases ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Argiriadi, Maria A, Goedken, Eric R, Banach, David, Borhani, David W, Burchat, Andrew, Dixon, Richard W, Marcotte, Doug, Overmeyer, Gary, Pivorunas, Valerie, Sadhukhan, Ramkrishna, Sousa, Silvino, Moore, Nigel St John, Tomlinson, Medha, Voss, Jeffrey, Wang, Lu, Wishart, Neil, Woller, Kevin, Talanian, Robert V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478977/
https://www.ncbi.nlm.nih.gov/pubmed/22995073
http://dx.doi.org/10.1186/1472-6807-12-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478977/
https://www.ncbi.nlm.nih.gov/pubmed/22995073
http://dx.doi.org/10.1186/1472-6807-12-22

Ejemplares similares